Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Clinical Oncology

• Publication date

  2005-08-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2005.66.130PMID 15955899
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Population Pharmacokinetics of CCI‐779: Correlations to Safety and Pharmacogenomic Responses in Patients with Advanced Renal Cancer

  2005cited by this paper
• Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results.

  2004cited by this paper
• Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

  2004cited by this paper
• Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

  2004cited by this paper
• The tor pathway: a target for cancer therapy

  2004cited by this paper
• Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells

  2004cited by this paper
• Mammalian target of rapamycin: a new molecular target for breast cancer.

  2003cited by this paper
• Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.

  2003cited by this paper
• Non-endocrine systemic therapies in advanced breast cancer

  2003cited by this paper
• Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.

  2003cited by this paper
• Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.

  2002cited by this paper
• Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.

  2001cited by this paper
• Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.

  2001cited by this paper
• Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.

  2001cited by this paper
• Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR

  2001cited by this paper
• mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group.

  1999cited by this paper
• Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy

  1999cited by this paper
• Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

  1999cited by this paper
• p70s6k Integrates Phosphatidylinositol 3-Kinase and Rapamycin-Regulated Signals for E2F Regulation in T Lymphocytes

  1999cited by this paper
• Studies on the mechanism of resistance to rapamycin in human cancer cells.

  1998cited by this paper
• Optimal two-stage designs for phase II clinical trials.

  1989cited by this paper
• CANCER OF THE BREAST

  1941cited by this paper

• MicroRNA dynamics, PTEN/PI3K/AKT signaling, and their relationship to breast cancer: prospects for pharmaceuticals and natural product application

  2025cites this paper
• Targeting mTOR Kinase for Cancer Treatment: A Comprehensive Review With Clinical Insights

  2025cites this paper
• Development of a prognostic model for breast cancer patients based on intratumoral tumor-infiltrating lymphocytes using machine learning algorithms

  2025cites this paper
• Synthesis, biological screening, and binding mode analysis of some N-substituted tetrahydroquinoline analogs as apoptosis inducers and anticancer agents

  2024cites this paper
• Temsirolimus inhibits FSP1 enzyme activity to induce ferroptosis and restrain liver cancer progression

  2024cites this paper
• A Meta-analysis of the Risk of Adverse Cardiovascular Events in Patients with Cancer Treated with Inhibitors of the PI3K/AKT/mTOR Signaling Pathway

  2024cites this paper
• Unraveling the interplay: exploring signaling pathways in pancreatic cancer in the context of pancreatic embryogenesis

  2024cites this paper
• Role of Molecular Targeted Therapeutic Drugs in Treatment of Breast Cancer: A Review Article

  2023cites this paper
• Roles of the PI3K/AKT Signalling Pathway in Cholangiocarcinoma: A Mini Review

  2023cites this paper
• Pomegranate-specific natural compounds as onco-preventive and onco-therapeutic compounds: Comparison with conventional drugs acting on the same molecular mechanisms

  2023cites this paper
• TMEM97/Sigma 2 Receptor Increases Estrogen Receptor α Activity in Promoting Breast Cancer Cell Growth

  2023cites this paper
• Hippocalcin-Like 1 blunts liver lipid metabolism to suppress tumorigenesis via directly targeting RUVBL1-mTOR signaling

  2022cites this paper
• Relationship between metabolic reprogramming and drug resistance in breast cancer

  2022cites this paper
• New and Emerging Targeted Therapies for Advanced Breast Cancer

  2022cites this paper
• Recent advances and limitations of mTOR inhibitors in the treatment of cancer

  2022cites this paper
• An overview on Estrogen receptors signaling and its ligands in breast cancer.

  2022cites this paper
• Screening the possible anti-cancer constituents of Hibiscus rosa-sinensis flower to address mammalian target of rapamycin: an in silico molecular docking, HYDE scoring, dynamic studies, and pharmacokinetic prediction

  2022cites this paper
• Discovery of potential mTOR inhibitors from Cichorium intybus to find new candidate drugs targeting the pathological protein related to the breast cancer: an integrated computational approach

  2022cites this paper
• Luminal A breast cancer resistance mechanisms and emerging treatments

  2021cites this paper
• Systemic Sirolimus Therapy for Infants and Children With Pulmonary Vein Stenosis.

  2021cites this paper
• Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors

  2021cites this paper
• Regulation of mRNA Translation by Hormone Receptors in Breast and Prostate Cancer

  2021cites this paper
• Programmed cell death, redox imbalance, and cancer therapeutics

  2021cites this paper
• A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies

  2021cites this paper
• The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside

  2021cites this paper
• In Silico Design and Experimental Validation of Combination Therapy for Pancreatic Cancer

  2020cites this paper
• MiR-145 alleviates Hcy-induced VSMC proliferation, migration, and phenotypic switch through repression of the PI3K/Akt/mTOR pathway

  2020cites this paper
• Synthetic lethality by targeting the RUVBL1/2-TTT complex in mTORC1-hyperactive cancer cells

  2020cites this paper
• MYC-binding lncRNA EPIC1 promotes AKT-mTORC1 signaling and rapamycin resistance in breast and ovarian cancer.

  2020cites this paper
• Antitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16)

  2020cites this paper
• 1β-OH-arenobufagin induces mitochondrial apoptosis in hepatocellular carcinoma through the suppression of mTOR signaling pathway.

  2020cites this paper
• Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer—Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy

  2019cites this paper
• An In silico Approach to Identify High Affinity Small Molecule Targeting m-TOR Inhibitors for the Clinical Treatment of Breast Cancer

  2019cites this paper
• The relation between PI3K/AKT signalling pathway and cancer.

  2019cites this paper
• Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer

  2019cites this paper
• A high-risk luminal A dominant breast cancer subtype with increased mobility

  2019cites this paper
• Cryptotanshinone Induces Cell Death in Lung Cancer by Targeting Aberrant Feedback Loops

  2019cites this paper
• Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors

  2019cites this paper
• Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer

  2018cites this paper
• mTOR Signalling Pathway-protein Expression in Post-transplant Cutaneous Squamous-cell Carcinomas Before and After Conversion to mTOR-inhibitors

  2018cites this paper
• Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases

  2018cites this paper
• Autophagy inducers in cancer

  2018cites this paper
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).

  2018cites this paper
• Everolimus induced mood changes in breast cancer patients: a case-control study

  2018cites this paper
• Controlled Release of Second Generation mTOR Inhibitors to Restrain Inflammation in Primary Immune Cells

  2017cites this paper
• Therapeutic Implications of Autophagy Inducers in Immunological Disorders, Infection, and Cancer

  2017cites this paper
• The human epidermal growth factor receptor 2 (HER2) in the breast cancer : from measurement to targeted treatment

  2017cites this paper
• Mood-stabilizing effects of rapamycin and its analog temsirolimus: relevance to autophagy

  2017cites this paper
• Osteoclast proton pump regulator Atp6v1c1 enhances breast cancer growth by activating the mTORC1 pathway and bone metastasis by increasing V-ATPase activity

  2017cites this paper
• mTOR function and therapeutic targeting in breast cancer.

  2017cites this paper
• Dysregulation of mRNA translation and energy metabolism in cancer.

  2017cites this paper
• 外科治疗Ⅲa期小细胞肺癌的疗效分析

  2017cites this paper
• MicroRNA-145 inhibits the activation of the mTOR signaling pathway to suppress the proliferation and invasion of invasive pituitary adenoma cells by targeting AKT3 in vivo and in vitro

  2017cites this paper
• Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors

  2017cites this paper
• Activation of the unfolded protein response in sarcoma cells treated with rapamycin or temsirolimus

  2017cites this paper
• Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression.

  2017cites this paper
• Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group

  2017cites this paper
• Targeting the Breast Cancer Kinome

  2017cites this paper
• Targeting PI3K/AKT/mTOR Pathway

  2017cites this paper
• Lung cancer in renal transplant recipients: A case-control study.

  2017cites this paper
• Cancer and mTOR Inhibitors in Transplant Recipients.

  2017cites this paper
• Advances in the treatment of advanced oestrogen-receptor-positive breast cancer.

  2017cites this paper
• Targeting PI 3 K / AKT / mTOR Pathway in the Breast Cancer Therapy

  2016cites this paper
• Recent Advances in Targeting Tumor Energy Metabolism with Tumor Acidosis as a Biomarker of Drug Efficacy

  2016cites this paper
• One-sided Dynamic Undersampling No-Propagation Neural Networks for imbalance problem

  2016cites this paper
• Expression of phosphorylated eIF4E-binding protein 1, but not of eIF4E itself, predicts survival in male breast cancer

  2016cites this paper
• Mammalian‐target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D‐MDS)

  2016cites this paper
• Targeting Oncoproteins for Molecular Cancer Therapy

  2016cites this paper
• mTOR inhibitor‐induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm

  2016cites this paper
• The therapeutic potential of mTOR inhibitors in breast cancer.

  2016cites this paper
• B cells grow up: Studies of B cell activation, proliferation and differentiation in primary antibody deficiencies

  2016cites this paper
• The role of PI3K and ERBB family gene mutations and other abnormalities in resistance to HER2-targeted therapies in HER2-positive breast cancer

  2016cites this paper
• The Role of mTOR Inhibitors in Breast Cancer

  2016cites this paper
• The Clinical Pharmacology and Toxicity Profile of Rapalogs

  2016cites this paper
• Safety of mTOR inhibitors in breast cancer

  2016cites this paper
• Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management.

  2016cites this paper
• Resistance to Aromatase Inhibitors in Breast Cancer

  2015influential citation
• Validation of p27KIP1 expression levels as a candidate predictive biomarker of response to rapalogs in patient-derived breast tumor xenografts

  2015cites this paper
• Targeting cancer with reovirus.

  2015cites this paper
• Development, Maintenance, and Reversal of Multiple Drug Resistance: At the Crossroads of TFPI1, ABC Transporters, and HIF1α

  2015cites this paper
• A preclinical evaluation of the PI 3 K alpha / delta dominant 3 inhibitor BAY 80-6946 in HER 2-positive breast cancer models 4 with acquired resistance to the HER 2-targeted therapies 5 trastuzumab and lapatinib 6

  2015cites this paper
• A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells.

  2015cites this paper
• C6 ceramide dramatically enhances docetaxel-induced growth inhibition and apoptosis in cultured breast cancer cells: a mechanism study.

  2015cites this paper
• Micheliolide Derivative DMAMCL Inhibits Glioma Cell Growth In Vitro and In Vivo

  2015cites this paper
• Ligand-Independent Signalling Through Estrogen Receptor Pathways in Breast Cancer

  2015cites this paper
• Treatment-related fatigue with everolimus and temsirolimus in patients with cancer—a meta-analysis of clinical trials

  2015cites this paper
• Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer

  2015cites this paper
• Targeted therapies for ER+/HER2- metastatic breast cancer

  2015cites this paper
• Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives.

  2015cites this paper
• mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction upon 4E-BP1 dephosphorylation

  2015cites this paper
• Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies.

  2015cites this paper
• Everolimus: a new hope for patients with breast cancer

  2014cites this paper
• Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer.

  2014cites this paper
• Everolimus: finding its place in the treatment of hormone receptor-positive advanced breast cancer

  2014cites this paper
• Patient-derived xenograft models: an emerging platform for translational cancer research.

  2014cites this paper
• Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis

  2014cites this paper
• Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro

  2014cites this paper
• Combination of themTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial

  2014cites this paper
• Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT

  2014cites this paper
• Signaling pathways in breast cancer: therapeutic targeting of the microenvironment.

  2014cites this paper